Quest Diagnostics Files 8-K

TL;DR

Quest Diagnostics filed an 8-K on Aug 29 for an Aug 23 event, details pending.

AI Summary

Quest Diagnostics Inc. filed an 8-K on August 29, 2024, reporting an event that occurred on August 23, 2024. The filing is related to financial statements and exhibits, and other events, but does not specify the exact nature of these events or any associated financial figures in the provided text.

Why It Matters

This filing indicates a material event or change for Quest Diagnostics, requiring disclosure to investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard disclosure form (8-K) and does not, in itself, indicate negative news or significant risk.

Key Players & Entities

• Quest Diagnostics Inc. (company) — Registrant
• August 23, 2024 (date) — Earliest Event Reported
• August 29, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• 500 Plaza Drive (address) — Principal executive offices
• Secaucus, NJ (location) — Principal executive offices location

FAQ

From the Filing

0001022079-24-000173.txt : 20240829 0001022079-24-000173.hdr.sgml : 20240829 20240829164143 ACCESSION NUMBER: 0001022079-24-000173 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240823 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240829 DATE AS OF CHANGE: 20240829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 241264350 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20240823.htm 8-K dgx-20240823 0001022079 false 0001022079 2024-08-23 2024-08-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : August 23, 2024 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01. Other Events On August 26, 2024, Quest Diagnostics Incorporated (the “Company”) announced that it has closed its previously announced acquisition of LifeLabs Inc. (“LifeLabs”), pursuant to the terms of an equity purchase agreement that the Company and its wholly owned subsidiary entered into with Borealis Infrastructure Corporation, BPC Health Trust, LifeLabs and BPC Lab Finance LP, an Ontario limited partnership, on July 2, 2024. LifeLabs provides laboratory diagnostic information and digital health connectivity systems in Canada. For more information on the LifeLabs acquisition, see the Company’s Current Report on Form 8-K filed on July 3, 2024 (the “Announcement Form 8-K”). The information contained in Announcement Form 8-K is not incorporated by reference into this Current Report on Form 8-K. &